drugset / Trial / NCT03274427
Treatment of Intermediate-stage Hepatocellular Carcinoma
Phase 3
Unknown
300 enrolled
The First Affiliated Hospital of Zhengzhou University
Anyang Tumor Hospital · collabFirst Affiliated Hospital of Xinjiang Medical University · collabFirst People's Hospital of Shangqiu · collabLuoyang Central Hospital · collabNanyang Central Hospital · collabShenma Medical Group General Hospital · collabThird People's Hospital of Jiaozuo · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with arginine hydrochloride and trimetazidine hydrochloride tablets in the treatment of patients with hepatocellular carcinoma.
Timeline
- Start
- 2017-07-18
- Primary completion
- 2021-07
- Completion
- 2021-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-arginine | Small molecule | 5 g | Intravenous |
| Subject | Trimetazidine | Small molecule | 40 mg | — |